Karpus Investment Management’s AbbVie ABBV Stock Holding History

Karpus Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$264K	Hold	1,050	–	–	0.01%	221
2026 Q1	$228K	Hold	1,050	–	–	0.01%	222
2025 Q4	$240K	Hold	1,050	–	–	0.01%	208
2025 Q3	$243K	Buy	+1,050	New	+$214K	0.01%	198
2025 Q2	–	Sell	-1,050	Closed	-$220K	–	200
2025 Q1	$220K	Buy	+1,050	New	+$204K	0.01%	197
2024 Q4	–	Sell	-1,050	Closed	-$207K	–	206
2024 Q3	$207K	Buy	+1,050	New	+$196K	0.01%	213

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Karpus Investment Management's ABBV Position: Q2 2026 in Review

Karpus Investment Management held its AbbVie (ABBV) position steady in Q2 2026 at 1,050 shares worth $264K. The position accounts for 0.01% of the portfolio, ranked #221.

Karpus Investment Management first reported a position in ABBV in Q3 2024 and has held it in 6 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Karpus Investment Management held 1,050 shares of AbbVie worth $264K as of Q2 2026.
Karpus Investment Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.01% of Karpus Investment Management's portfolio in Q2 2026, its #221 holding.
Karpus Investment Management first reported a position in AbbVie in Q3 2024 and has held it in 6 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Karpus Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.